Applicability of bedside ultrasonography for the diagnosis of deep venous thrombosis in patients with COVID ‐19 and treatment with low molecular weight heparin

Purpose The aim of this study was to evaluate the applicability of bedside ultrasonography for the diagnosis of deep venous thrombosis (DVT) in patients infected with corona virus disease 2019 (COVID‐19) with and without treatment with low molecular weight heparin (LMWH). Methods We retrospectively analyzed the records of deceased and surviving patients in whom ultrasonography detected or not a DVT, and in whom LMWH was or not prescribed. Results The incidence of DVT is higher in the deceased (33/35) than in the surviving (22/46) patients. LMWH was administered in a larger proportion of surviving (18/22) than of deceased (18/33) patients. D‐dimer concentrations decreased in patients who received LMWH in both groups. Conclusions There was a high incidence of DVT in patients who succumbed to COVID‐19. Bedside ultrasonography can detect the presence of DVT as early as possible and help assessing the risk of venous thromboembolism, allowing early and reasonable use of LMWH.